Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
William Frank Hulse IV, General Counsel and Chief Administrative Officer of Mimedx Group, Inc. (NASDAQ:MDXG), a $1.16 billion market cap company currently trading near $7.92, recently sold shares totaling $430,762. The transactions, dated March 13, 2025, involved the sale of 54,596 shares at a price of $7.89 each. According to InvestingPro analysis, the stock has shown significant momentum with a 27% gain over the past six months.
According to the Form 4 filed with the Securities and Exchange Commission, Hulse sold 34,230 shares and 20,366 shares in two separate transactions. These sales were made to cover tax withholding liabilities associated with the vesting of previously granted performance and restricted stock unit awards. Notably, analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $12 to $16.
Following these transactions, Hulse retains ownership of 440,178 shares in the company. The company maintains a "GREAT" financial health score according to InvestingPro, which offers comprehensive analysis and additional insights through its detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, MiMedx Group Inc . reported strong financial results for the fourth quarter of 2024. The company surpassed earnings expectations with an EPS of $0.07, beating the forecast of $0.06. Revenue for the quarter was $93 million, exceeding the anticipated $89.4 million and reflecting a 7% increase from the previous year. MiMedx ended the year with $104 million in cash, a $16 million increase during the fourth quarter. Additionally, the company projects high single-digit sales growth for 2025. Despite these positive results, MiMedx’s stock experienced a slight decline in after-hours trading. The company continues to face potential challenges, including changes in Medicare Local Coverage Determination and ongoing legal disputes. Analysts from firms such as Craig Hallum Capital Group have shown interest in MiMedx’s strategic plans and potential market opportunities, particularly regarding new product releases like Heliogen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.